UK and US based biotech firm Orchard Therapeutics has secured funding of $150m to expand its work in gene therapy. The financing followed the company’s acquisition in two years ago of GlaxoSmithKline’s portfolio of rare disease gene therapies, and builds on previous financing of $140m.
UK and US based biotech firm Orchard Therapeutics has secured funding of $150m to expand its work in gene therapy. The financing followed the company’s acquisition in April of GlaxoSmithKline’s portfolio of rare disease gene therapies, and builds on previous financing of $140m.